Since the GranuFlo recall, our firm has heard from dialysis patients on a regular basis who suffered life-threatening heart problems, allegedly due to GranuFlo or NaturaLyte. We are pleased to see the GranuFlo litigation moving forward.
New York, NY (PRWEB) November 04, 2013
The federal court overseeing hundreds of GranuFlo lawsuits (http://www.thegranuflolawsuit.com/) filed in the wake of last year’s recall of GranuFlo and NaturaLyte dialysis drugs held a Status Conference on November 1, 2013, Bernstein Liebhard LLP reports. According to court documents filed in U.S. District Court, District of Massachusetts, the Court took up a number of motions pending in the litigation. In a Notice filed on October 31st, attorneys representing Fresenius Medical Care reported that some of those motions were filed by dialysis lawsuit plaintiffs seeking to have their cases remanded back to the state courts where they were originally filed. (In re Fresenius GranuFlo/Naturalyte Dialysate Litigation, MDL No. 2428)
“Since the GranuFlo recall, our firm has heard from dialysis patients on a regular basis who suffered life-threatening heart problems, allegedly due to GranuFlo or NaturaLyte. We are pleased to see the GranuFlo litigation moving forward,” says Bernstein Liebhard LLP, a nationwide law firm representing victims of defective drugs and medical devices. The Firm is currently offering free GranuFlo lawsuit evaluations to dialysis patients who suffered cardiac arrest, heart attacks, stroke, sudden cardiac death or other side effects allegedly related to the administration of GranuFlo and NaturaLyte during dialysis treatments.
Court records indicate that at least 312 dialysis lawsuits have been filed in the District of Massachusetts on behalf of individuals who were allegedly harmed by GranuFlo or NaturaLyte. Additional claims involving similar allegations are also pending at the state level in Massachusetts’ Middlesex County Superior Court. (In re Consolidated Fresenius Cases, No. MICV2013-03400-O). All of the GranuFlo lawsuits involve similar allegations that Fresenius Medical Care failed to provide adequate warnings regarding the use of GranuFlo and NaturaLyte, and continued to aggressively market both products after their risks became apparent in order to protect their market share.
GranuFlo and NaturaLyte are used during dialysis to remove acid from the blood. In March 2012, an Urgent Product Notification issued by Fresenius Medical Care warned of sudden, life-threatening heart problems that could occur due to inappropriate dosing of the drugs. The New York Times reported in June 2012 that many doctors were unaware that, compared to rival products, GranuFlo and NaturaLyte contained more of an ingredient the body converts to bicarbonate. As such, certain dosages could result in dangerously elevated levels of bicarbonate in the blood, resulting in metabolic alkalosis, a condition that can cause deadly heart problems in dialysis patients.*
In June 2012, the U.S. Food & Drug Administration (FDA) granted Class I recall status to Fresenius Medical Care’s Urgent Product Notification, which indicates that a medical product poses a significant risk of serious injury or death. According to The Times, the agency also began investigating Fresenius Medical Care shortly after learning of a memo the company had issued in November 2011 to its own clinics that warned of the heart risks associated with GranuFlo and NaturaLyte. The agency is trying to determine if Fresenius violated federal regulations, as none of its customer clinics outside of the Fresenius network were issued a similar warning about GranuFlo and NaturaLyte at that time.
Individuals treated with GranuFlo or NaturaLyte, or their families, may be entitled to file a dialysis lawsuit against Fresenius Medical Care if they or their loved one suffered cardiac arrest, heart attack, stroke, or sudden cardiac death, within 72 hours of a dialysis treatment with one of these drugs. Learn More about the GranuFlo recall at Bernstein Liebhard LLP’s website. For additional information, and to arrange for a free case review, please call 800-511-5092.
*nytimes.com/2012/06/15/health/fda-investigates-fresenius-for-failure-to-warn-of-risk.html; New York Times, June 14, 2012
About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993, including those who have been harmed by dangerous drugs, defective medical devices and consumer products. The firm has been named by The National Law Journal to the “Plaintiffs’ Hot List,” recognizing the top plaintiffs’ firms in the country, for the past 11 consecutive years.
Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
ATTORNEY ADVERTISING. © 2013 Bernstein Liebhard LLP. The law firm responsible for this
advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Felecia L. Stern, Esq.
Bernstein Liebhard LLP